搜索结果: 1-15 共查到“医学 BENIGN PROSTATIC HYPERPLASIA”相关记录21条 . 查询时间(0.055 秒)
Physical Activity and Benign Prostatic Hyperplasia-Related Outcomes and Nocturia
BENIGN PROSTATIC HYPERPLASIA LOWER URINARY TRACT SYMPTOMS NOCTURIA PHYSICAL ACTIVITY
2017/4/14
Introduction: Benign prostatic hyperplasia (BPH) and its associated lower urinary tract symptoms (LUTS), including nocturia, are extremely common among middle- and older-age American men. Although stu...
Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder
urinary tract symptoms urinary ATP
2009/12/16
We investigated whether the improvement of lower urinary tract symptoms (LUTS) and urinary adenosine triphosphate (ATP) level were related. Fifty-seven patients and 13 normal controls were enrolled in...
Histologic Evaluation in Patients with Benign Prostatic Hyperplasia Treated with Finasteride and Surgery Alone
5 alpha-reductase inhibitor morphometric analysis Histology of benign prostatic hyperplasia
2009/7/3
In this study, we compared stroma, epithelium, glandular lumen, smooth muscle hyperplasia, inflammation and fibrous components in benign prostatic hyperplasia (BPH) tissue between the group undergone ...
Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia（BPH）
Testosterone DHT 3cs-androstanediol
2009/2/17
Benign prostatic hyperplasia (BPH) is an androgen-dependent disease that initially develops in the inner prostate, where the highest concentrations of testosterone (T) and dihydrotestosterone (DHT) ...
Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia（BPH
Testosterone DHT 3cs-androstanediol
2009/2/17
Benign prostatic hyperplasia (BPH) is an androgen-dependent disease that initially develops in the inner prostate, where the highest concentrations of testosterone (T) and dihydrotestosterone (DHT) ...
Estrogen receptor messenger RNA expression in human benign prostatic hyperplasia：detection, localization, and modulation with a long-acting gonadotropin-releasing hormone agonist
Estrogen receptor messenger RNA expression human benign prostatic hyperplasia detection localization
2009/2/12
We have analyzed human benign prostatic hyperplastic (BPH) tissue derived from eight radical prostatectomy specimens from patients with prostate cancer for the expression of the estrogen receptor ...
A permanent, epithelializing stent for the treatment of benign prostatic hyperplasia. Preliminary results
Prosthesis prostatic enlargement prostatic
2009/2/7
Currently, there is much enthusiasm in the urologic community for the development of alternative treatments to transurethral prostatectomy for management of benign prostatic hyperplasia (BPH). At the ...
Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia
Treatment benign prostatic hyperplasia flutamide
2009/2/7
Patients diagnosed as having benign prostatic hyperplasia (BPH) had determination of prostate volume (PV), prostate-specific antigen (PSA), and serum testosterone before consideration for entry into...
One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group
Finasteride benign prostatic hyperplasia (BPH)
2009/2/7
Finasteride (MK-906) is a 5 alpha-reductase inhibitor that reduces circulating dihydrotestosterone (DHT) levels without lowering testosterone levels. The goal of this study was to evaluate the e...
Local microwave hyperthermia as a treatment alternative for benign prostatic hyperplasia
Local microwave hyperthermia benign prostatic hyperplasia
2009/2/7
It appears that the technology for local microwave application of heat to the prostate for the management of benign prostatic hyperplasia has arrived. There are a number of issues to be resolved in ...
Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia
aromatase inhibitor management benign prostatic hyperplasia
2009/2/7
Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. Its pharmacologic action has been evaluated in mice, rats, rabbits, dogs, monkeys, and humans. In rats, atame...
Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies
aromatase inhibitors prostatic hyperplasia Experimental studies
2009/2/7
Today, human benign prostatic hyperplasia (BPH) is considered primarily to be a disease of the stroma, in which estrogens are thought to play a considerable causative or permissive role. The growi...
The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia
Benign prostatic hyperplasia alpha blockade
2009/2/7
The rationale for using alpha blockade to treat benign prostatic hyperplasia (BPH) is based on the physiology and pharmacology of prostate smooth muscle. Approximately 20% of the area density of the...
LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia
Prostatic enlargement alternative treatments for prostatic enlargement antiandrogen therapy
2009/2/7
Luteinizing hormone-releasing hormone (LHRH) agonist, when administered in a continuous, nonpulsatile manner, causes desensitization of the LHRH receptor complex on the gonadotroph cells in the an...
The pathophysiology of benign prostatic hyperplasia
Prostatic growth prostatic smooth muscle prostatism
2009/2/7
Although benign prostatic hyperplasia (BPH) is one of the most common disease processes affecting the aging male, surprisingly little is known about its pathophysiology. Cause-and-effect relation...